Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY GRANTS RSUS AND STOCK OPTIONS AND SETTLES DEBT

The Precision Peptide Company Inc. has granted restricted share units (RSUs) and incentive stock options pursuant to the company's omnibus share incentive plan, as well as the issuance of common shares to settle outstanding indebtedness owed to a creditor of the company.

RSU grant

The company has granted a total of 600,000 RSUs to certain director of the company. Of the RSUs granted, 300,000 RSUs will vest on June 15, 2026, and 300,000 RSUs will vest on Jan. 15, 2027. All RSUs are subject to the terms of the plan and applicable securities laws.

Stock option grant

The company has granted a total of 1.1 million options to certain directors, officers and/or consultants of the company. Each option entitles the holder to acquire one common share of the company at an exercise price of 50 cents per share for a period of three years from the date of grant. All options are subject to the terms of the plan and applicable securities laws.

The company notes that it has elected not to proceed with the issuance of the options announced in its April 16, 2026, news release and that the issuance disclosed above is in lieu of the April 16, 2026, proposed option grants.

Shares for debt

The company has agreed to settle outstanding indebtedness in the amount of $125,000, representing a cash bonus owing to the chief executive officer of the company, through the issuance of 300,000 common shares at a deemed price of approximately 42 cents per share. All shares issued pursuant to the share-for-debt settlement will be subject to a statutory four-month hold period in accordance with applicable securities laws.

The debt settlement constitutes a related party transaction as defined in Multilateral Instrument 61-101, Protection of Minority Securityholders in Special Transaction. The company is relying on the exemption from valuation requirement and minority approval pursuant to subsections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as the participation by an insider of the company in the debt settlement does not represent more than 25 per cent of the fair market value of the company's market capitalization.

About The Precision Peptide Company Inc.

Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.